View Item 

Show simple item record

Cardiovascular actions of the hypotensive agent, N, N-diallylmelamine (U-7720)
dc.contributor.authorDucharme, Donald W.en_US
dc.contributor.authorWeeks, James R.en_US
dc.contributor.authorFreyburger, Walter A.en_US
dc.date.accessioned2006-09-11T17:36:58Z
dc.date.available2006-09-11T17:36:58Z
dc.date.issued1965-01en_US
dc.identifier.citationFreyburger, Walter A.; Weeks, James R.; Ducharme, Donald W.; (1965). "Cardiovascular actions of the hypotensive agent, N, N-diallylmelamine (U-7720)." Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie 251(1): 39-47. <http://hdl.handle.net/2027.42/46303>en_US
dc.identifier.issn0028-1298en_US
dc.identifier.issn1432-1912en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46303
dc.description.abstractDiallylmelamine is an effective hypotensive agent in hypertensive dogs and rats, having a duration of action exceeding twenty-four hours from a single oral dose. It has limited efficacy in normotensive rats. Hypotensive activity of gradual onset is preceded by a latent period of up to two hours and becomes maximal six hours or more after dosing. This agent does not depress cardiac output or sympathetic vasoconstrictor activity. It is suggested that its hypotensive activity results from a direct effect upon vascular smooth muscle.en_US
dc.format.extent418054 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherNeurosciencesen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.titleCardiovascular actions of the hypotensive agent, N, N-diallylmelamine (U-7720)en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumFrom the Pharmacology Research Laboratories, The Upjohn Company Kalamazoo, Michigan; Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherFrom the Pharmacology Research Laboratories, The Upjohn Company Kalamazoo, Michiganen_US
dc.contributor.affiliationotherFrom the Pharmacology Research Laboratories, The Upjohn Company Kalamazoo, Michiganen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46303/1/210_2004_Article_BF00245728.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00245728en_US
dc.identifier.sourceNaunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologieen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
210_2004_Article_BF00245728.pdf
Size:
408.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.